Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10475
Title: Interleukin-21 signaling: functions in cancer and autoimmunity.
Austin Authors: Davis, Ian D;Skak, Kresten;Smyth, Mark J;Kristjansen, Paul E G;Miller, Dennis M;Sivakumar, Pallavur V
Affiliation: Ludwig-Austin Joint Medical Oncology Unit, Austin Health, Melbourne, Australia
Issue Date: 1-Dec-2007
Publication information: Clinical Cancer Research; 13(23): 6926-32
Abstract: Interleukin-21 (IL-21) is a cytokine with structural and sequence homology to IL-2 and IL-15, yet possesses several biological properties distinct from these cytokines. IL-21 is produced mainly by activated CD4(+) T cells and natural killer T cells and mediates its activity by binding to the IL-21 receptor (IL-21R), consisting of an IL-21-specific alpha chain (IL-21Ralpha; JAK/STAT) that heterodimerizes with the common gamma chain (CD132). Intracellular signaling occurs through the Janus-activated kinase/signal transducer and activator of transcription pathways. Physiologic expression of IL-21R is restricted to lymphoid tissues and peripheral blood mononuclear cells; however, other tissues such as epithelium, synovium, or transformed cells can acquire expression of both components of IL-21R heterodimer. IL-21 has complex activities on a wide variety of cell types, leading to enhancement of adaptive T-cell immunity, antibody production, activation of natural killer cell subtypes, and opposition to suppressive effects mediated by regulatory T cells. Functionally, these activities promote immune responses and point to a physiologic role of IL-21 in autoimmunity and immune enhancement. Therapeutic manipulation of IL-21 activity may allow improved immunotherapy for cancer as well as insights into autoimmune disease. Recently conducted phase 1 trials in metastatic melanoma and renal cell carcinoma have shown that recombinant IL-21 has a favorable safety profile and support its continued investigation as a potential anticancer drug.
Gov't Doc #: 18056166
URI: http://ahro.austin.org.au/austinjspui/handle/1/10475
DOI: 10.1158/1078-0432.CCR-07-1238
URL: https://pubmed.ncbi.nlm.nih.gov/18056166
Type: Journal Article
Subjects: Animals
Autoimmunity.physiology
Humans
Interleukins.immunology.metabolism.therapeutic use
Neoplasms.immunology.metabolism.therapy
Receptors, Interleukin-21.immunology.metabolism
Signal Transduction
Appears in Collections:Journal articles

Show full item record

Page view(s)

12
checked on Dec 1, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.